Psoriasis

Results from a recent study suggested a possible increased risk of serious cardiovascular events among patients with high cardiovascular risk before initiating ustekinumab.

Findings from a recent analysis of phase 3 AMAGINE-2 and AMAGINE-3 trials showed greater benefit with brodalumab compared with ustekinumab for patients with psoriasis.

A recent study demonstrated the safety and long-term effectiveness of bimekizumab, with participants maintaining high PASI scores through 60 weeks of treatment.

Psoriasis is associated with many comorbid conditions. In an interview with The Dermatologist, Ronald Prussick, MD, discusses the latest research on these comorbidities, evidence on lifestyle and treatment options that could potentially prevent or manage both psoriasis and comorbid conditions, and the importance of screening and aggressively treating psoriatic arthritis.